Yeast Study Reveals New Treatment Path for Huntington's
Author: University of Leicester
Published: 2011/01/10 - Updated: 2025/12/15
Publication Details: Peer-Reviewed, Research, Study, Analysis
Category Topic: Neurological Disorders - Related Publications
Page Content: Synopsis - Introduction - Main - Insights, Updates
Synopsis: This research represents peer-reviewed scientific work published in The Journal of Biological Chemistry, documenting a collaborative effort between universities in Leicester, Lisbon, and San Francisco that employed baker's yeast as a model organism to study Huntington's disease mechanisms. The study holds particular value for families affected by this inherited neurodegenerative condition because it identifies cellular translation processes - previously unconnected to Huntington's - as potential therapeutic targets, which matters significantly given that no current treatments can halt or slow disease progression. The genomics profiling approach proved authoritative enough to reveal protective gene networks that, if validated through further research, could guide development of pharmacological interventions similar to those showing promise in Parkinson's disease treatment. For the roughly 6-7 per 100,000 people affected by Huntington's, including those who develop symptoms in adulthood and the smaller percentage diagnosed before age 20, this work offers a concrete scientific foundation for future clinical applications - Disabled World (DW).
Introduction
Hope for new ways of treating devastating neurodegenerative disorders such as Huntington's disease has been raised by a trans-Atlantic team of researchers thanks to the use of cutting-edge genetic techniques.
Led by the University of Leicester, scientists from the University of Lisbon (led by Dr Tiago Outeiro) and University of California at San Francisco (led by Dr Paul Muchowski) collaborated to generate novel approaches for tackling the diseases. Their work, funded by the Medical Research Council, is published in The Journal of Biological Chemistry.
Main Content
At Leicester, working simply with baker's yeast, a team of biological scientists examined aspects of Huntington's disease. These yeast are extremely well-characterized and have powerful and facile genetics which allow researchers to rapidly interrogate this system at a genome-wide level. Research in recent years has found that baker's yeast can be used to study mechanisms underlying disease pathology, and this simple organism has been used to identify several promising candidate drug targets for neurodegenerative disorders, including Huntington's disease.
Flaviano Giorgini, lead author of the research paper at the University of Leicester, said:
"My research group is interested in using genetics and genomics approaches to better understand the fatal neurodegenerative disorders of Huntington's disease and Parkinson's disease."
"By clarifying the genes and cellular pathways involved in these diseases we hope to identify novel strategies for treatment and therapy of these disorders. In our work we use simple, yet powerful genetic organisms such as baker's yeast and fruit flies to model aspects of these devastating diseases."
"In the current study we have used a novel functional genomics profiling approach to identify genes which can protect these simple organisms from disease symptoms. We then used computational approaches to uncover a network of interactions amongst these genes, which has shed light on the mechanisms underlying this disorder."
Using the approach above, the scientists found that many of the protective genes are involved in translation - a cellular process in which messenger RNA (mRNA) is decoded by the ribosome to produce specific proteins. This is particularly intriguing as this process has not been implicated in Huntington's disease in the past.
This is important because recent work indicates that pharmacological modulation of translation may represent a promising avenue for treatment of Parkinson's disease. Therefore, this new research strongly dovetails with these observations and suggests that similar drug treatment may be beneficial in Huntington's disease.
Dr Giorgini, of the Department of Genetics, said:
"Our research has taken advantage of cutting edge genomics approaches using a simple model organism to identify a novel area for potential therapeutic intervention for Huntington's disease."
"If our findings are validated by further studies, it might suggest a novel therapeutic approach for this devastating disorder - which is critical as currently there are no treatments for onset or progression of symptoms."
Huntington's Disease Facts
- Huntington's disease is an inherited disease of the brain.
- There is no cure for Huntington's disease and its progress cannot be reversed or slowed down.
- Both men and women with a family history of Huntington's can inherit the disease and symptoms usually start to show in adulthood.
- Early symptoms such as personality changes, mood swings and bizarre behavior are often overlooked at first and attributed to something else.
- Huntington's disease was originally called Huntington's chorea, after the Greek word for dancing, as the associated involuntary movements can look like jerky dancing.
- UK studies have found that approximately 6-7 people per 100,000 of the population are affected by Huntington's disease. However, it is likely that the true figure is much higher.
- Medication can be used to manage some of the symptoms, and therapies (such as speech and language therapy and occupational therapy) can help with communication and day-to-day living.
- Juvenile (children's) Huntington's disease develops before the age of 20 years. Only 5-10% of people with Huntington's develop the condition at a very young age, and the pattern of features may be different.
- The disease damages the nerve cells in the brain, causing deterioration and gradual loss of function of areas of the brain. This affects movement, cognition (perception, awareness, thinking, judgment) and behavior.
Citation:
Functional Gene Expression Profiling in Yeast Implicates Translational Dysfunction in Mutant Huntington Toxicity, The Journal of Biological Chemistry, Vol. 286, Issue 1, 410-419, JANUARY 7, 2011. Eran Tauber; Leonor Miller-Fleming; Robert P. Mason; Jannine Clapp; Nicola J. Butler; Flaviano Giorgini University of Leicester; Leonor Miller-Fleming; Tiago F. Outeiro Universidade de Lisboa; Wanda Kwan; Paul J. Muchowski University of California at San Francisco.
Article #10.1074/jbc.M110.101527
Insights, Analysis, and Developments
Editorial Note: The Leicester team's decision to work with baker's yeast - an organism separated from humans by hundreds of millions of years of evolution - underscores both the universality of certain cellular mechanisms and the creative pragmatism required in modern disease research. While the path from yeast genetics to human therapeutics remains long and uncertain, the identification of translation dysfunction as a factor in Huntington's toxicity opens a research avenue that had been hiding in plain sight. The real test will come as these findings move through validation studies and, potentially, into clinical trials where the theoretical promise of modulating protein synthesis must prove itself against the brutal reality of a disease that has, until now, resisted all attempts at meaningful intervention - Disabled World (DW).Attribution/Source(s): This peer reviewed publication was selected for publishing by the editors of Disabled World (DW) due to its relevance to the disability community. Originally authored by University of Leicester and published on 2011/01/10, this content may have been edited for style, clarity, or brevity.